PH21092A - Enteric film coating composition - Google Patents

Enteric film coating composition

Info

Publication number
PH21092A
PH21092A PH31222A PH31222A PH21092A PH 21092 A PH21092 A PH 21092A PH 31222 A PH31222 A PH 31222A PH 31222 A PH31222 A PH 31222A PH 21092 A PH21092 A PH 21092A
Authority
PH
Philippines
Prior art keywords
coating composition
film coating
enteric film
enteric
composition
Prior art date
Application number
PH31222A
Other languages
English (en)
Inventor
Stuart C Porter
Edward J Woznicki
Susan M Grillo
Andrea Louis F D
Original Assignee
Colorcon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colorcon filed Critical Colorcon
Publication of PH21092A publication Critical patent/PH21092A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
PH31222A 1983-09-19 1984-09-17 Enteric film coating composition PH21092A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/533,541 US4556552A (en) 1983-09-19 1983-09-19 Enteric film-coating compositions

Publications (1)

Publication Number Publication Date
PH21092A true PH21092A (en) 1987-07-16

Family

ID=24126414

Family Applications (1)

Application Number Title Priority Date Filing Date
PH31222A PH21092A (en) 1983-09-19 1984-09-17 Enteric film coating composition

Country Status (8)

Country Link
US (1) US4556552A (OSRAM)
EP (1) EP0156852A1 (OSRAM)
JP (1) JPS60502207A (OSRAM)
KR (1) KR850700009A (OSRAM)
AU (1) AU3397184A (OSRAM)
IT (1) IT8448873A0 (OSRAM)
PH (1) PH21092A (OSRAM)
WO (1) WO1985001207A1 (OSRAM)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971791A (en) * 1985-08-26 1990-11-20 The Procter & Gamble Company Taste masking compositions
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US4857337A (en) * 1988-05-24 1989-08-15 American Home Products Corp. (Del) Enteric coated aspirin tablets
DE69127470T2 (de) 1990-03-02 1998-02-19 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
FR2660317B1 (fr) * 1990-03-27 1994-01-14 Seppic Produit filmogene destine a l'enrobage des formes solides; son procede de fabrication et produits revetus de ce produit.
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5427614A (en) * 1992-02-14 1995-06-27 Warner-Lambert Company Starch based formulations
US6224911B1 (en) * 1993-03-16 2001-05-01 Syntex (U.S.A.) Llc Process for the preparation of enteric coated pharmaceutical dosage forms
US5436011A (en) * 1993-04-16 1995-07-25 Bristol-Myers Squibb Company Solid pharmaceutical dosage form and a method for reducing abrasion
US6113893A (en) * 1993-07-28 2000-09-05 Pfizer Inc. Psoriasis treatment
US5800831A (en) * 1993-07-28 1998-09-01 Pfizer Inc. Psoriasis treatment with polymer film
WO1995006462A1 (en) * 1993-08-30 1995-03-09 Warner-Lambert Company Tablet coating based on a melt-spun mixture of a saccharide and apolymer
CZ289804B6 (cs) * 1994-07-08 2002-04-17 Astrazeneca Ab Multijednotková tabletovaná dávková forma I
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US6645943B1 (en) 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US6608035B1 (en) 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5683718A (en) * 1995-04-04 1997-11-04 Time-Cap Labs, Inc. Enteric coated tablet with raised identification character and method of manufacture
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US7074768B2 (en) 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US6624293B1 (en) 1995-08-17 2003-09-23 Hybridon, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US5807580A (en) * 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
WO1999009154A2 (en) * 1997-08-19 1999-02-25 Hybridon, Inc. Novel hiv-specific synthetic oligonucleotides and methods of their use
DE69815003T2 (de) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6300320B1 (en) 1999-01-05 2001-10-09 Isis Pharmaceuticals, Inc. Modulation of c-jun using inhibitors of protein kinase C
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
WO2001089557A2 (en) 2000-05-24 2001-11-29 The United States Of America, As Represented By Secretary Of The Department Of Health & Human Services Methods for preventing strokes by inducing tolerance to e-selectin
JP2004517066A (ja) 2000-11-20 2004-06-10 ダウ グローバル テクノロジーズ インコーポレイティド 水吸収性ポリマーの生体内での使用
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
EP1339395A2 (en) 2000-11-28 2003-09-03 Fmc Corporation Edible pga (propylene glycol alginate) coating composition
EP1404323B1 (en) * 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
CA2483827C (en) * 2002-04-29 2012-01-24 Amir H. Shojaei Pharmaceutical formulations with improved bioavailability
CN100363007C (zh) * 2002-07-29 2008-01-23 葛兰素集团有限公司 含拉莫三嗪的缓释制剂
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AU2004229464A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
JP2006522817A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
HRP20150037T4 (hr) * 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
US20040202755A1 (en) * 2003-04-08 2004-10-14 Myers Gale D. Speckled confection pieces
CN1984921B (zh) 2003-06-03 2010-06-16 Isis药物公司 存活蛋白表达的调节
DK2210605T3 (en) * 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
HUE029189T2 (en) 2004-02-06 2017-02-28 Pharmatel (R&D) Pty Ltd As Trustee For The Pharmatel (R & D) Trust The use of aminosalicylates in diarrhea prodominant irritable bowel syndrome
NZ554277A (en) 2004-10-20 2010-09-30 Antisense Therapeutics Ltd Antisense modulation of integrin alpha 4 expression
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
CN101137378A (zh) * 2005-01-20 2008-03-05 普罗热尼奇制药公司 甲基纳曲酮和相关化合物治疗术后胃肠功能障碍的用途
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
EP2097487B1 (en) * 2007-01-05 2013-02-20 Basf Se Co-milling organic pigments with fumed silica
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
KR101730290B1 (ko) 2007-05-11 2017-04-25 토마스 제퍼슨 유니버시티 신경변성 질환 및 장애의 치료 및 예방 방법
CN101687009A (zh) * 2007-05-11 2010-03-31 宾夕法尼亚大学理事会 治疗皮肤溃疡的方法
RU2010123692A (ru) * 2007-11-13 2011-12-20 Геркулес Инкорпорейтед (Us) Диспергируемая в воде композиция энтеросолюбильного покрытия для нутрицевтических и фармацевтических лекарственных форм
HUE041715T2 (hu) * 2007-12-21 2019-05-28 Dr Willmar Schwabe Gmbh & Co Kg Ginkgo biloba levél-kivonat alkalmazása
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2729582C (en) 2008-07-01 2017-09-19 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
US20100034959A1 (en) * 2008-08-07 2010-02-11 Vector Corporation High solids, high molecular weight polymer coating
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ES2847883T3 (es) 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
WO2013045352A1 (de) 2011-09-30 2013-04-04 Basf Se Verfahren zur herstellung von festen pigmenthaltigen filmüberzugsmitteln in form von granulaten auf basis von magensaftresistenten filmbildnern für pharmazeutische dosierungsformen
US9173884B2 (en) 2011-11-30 2015-11-03 Trustees Of Boston College Inhibitors of phosphodiesterase 11 (PDE11)
WO2013079696A1 (en) 2011-12-01 2013-06-06 Glaxo Group Limited Methods of treatment and prevention of eye diseases
US8277842B1 (en) * 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use
CA2908096C (en) 2013-03-27 2022-05-03 Isarna Therapeutics Gmbh Modified tgf-beta oligonucleotides
CA3002137A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
DK3420084T3 (da) 2016-02-26 2021-10-25 Secarna Pharmaceuticals Gmbh & Co Kg Hidtil ukendt tilgang til behandling af inflammatoriske forstyrrelser
EP3211081A1 (en) 2016-02-26 2017-08-30 Secarna Pharmaceuticals GmbH & Co. KG Novel approach for treating inflammatory disorders
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
KR102519171B1 (ko) 2016-10-07 2023-04-07 세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지 암 치료를 위한 새로운 접근법
EP4520828A3 (en) 2016-11-15 2025-07-09 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
WO2019070917A1 (en) 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
WO2019099560A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
JP2022531415A (ja) 2019-05-03 2022-07-06 セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー 腫瘍の処置に使用するためのｐｄ－ｌ１アンチセンスオリゴヌクレオチド

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2455790A (en) * 1945-06-09 1948-12-07 Eastman Kodak Co Enteric coatings
CH283585A (de) * 1950-03-15 1952-06-15 Hoffmann La Roche Zur Herstellung von Tablettenüberzügen geeignetes Gemisch.
US2897122A (en) * 1956-10-04 1959-07-28 Frosst & Co Charles E Enteric coated product
US2993837A (en) * 1959-07-13 1961-07-25 Frosst & Co Charles E Enteric coated tablets
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
US3449489A (en) * 1965-10-21 1969-06-10 William E Gaunt Pharmaceutical compositions and their preparation
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
DE2612889B1 (de) * 1976-03-26 1977-09-01 Basf Ag UEberzugsmittel fuer Arzneiformlinge
JPH027925B2 (OSRAM) * 1978-10-02 1990-02-21 Purdue Research Foundation
BE886416A (fr) * 1979-11-29 1981-03-16 Colorcon Composition de revetement comestible seche formant une pelicule, son procede de preparation et produits revetus de ladite composition
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form

Also Published As

Publication number Publication date
IT8448873A0 (it) 1984-09-18
JPS60502207A (ja) 1985-12-19
AU3397184A (en) 1985-04-11
US4556552A (en) 1985-12-03
EP0156852A1 (en) 1985-10-09
KR850700009A (ko) 1985-10-21
JPH0534333B2 (OSRAM) 1993-05-21
WO1985001207A1 (en) 1985-03-28

Similar Documents

Publication Publication Date Title
GB8328632D0 (en) Coating composition
GB8330075D0 (en) Waterbore coating composition
GB2149409B (en) Coating composition
GB8401356D0 (en) Coating
ZW17084A1 (en) Coating compositions
GB2190091B (en) Coating composition
DE3478812D1 (en) Coating resin composition
GB8420740D0 (en) Coating compositions
GR82536B (en) Improved surface coating compositions
GB8315609D0 (en) Coating compositions
DE3460518D1 (en) Siloxane-pva coating compositions
GB2145099B (en) Coating compositions
GB2147307B (en) Thermoplastic coating compositions
GB8333542D0 (en) Coating composition
GB2118192B (en) Coating composition
ZA842681B (en) Coating compositions
GB2140813B (en) Coating composition
GB8413825D0 (en) Coating
GB8322028D0 (en) Coating composition
GB2141127B (en) Coating compositions
GB8423251D0 (en) Coating
GB8429989D0 (en) Coating composition
GB2130591B (en) Coating composition
GB2150051B (en) Coating surfaces
GB8405007D0 (en) Coating composition